학술논문
915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S660-S661
Subject
Language
ISSN
0923-7534